Autologous stromal vascular fraction cells: A tool for facilitating tolerance in rheumatic disease

Cellular Immunology

Volumn 264, Issue 1, 2010, Pages 7-17

  Ichim, Thomas E ^a   Harman, Robert J ^b   Min, Wei Ping ^c   Minev, Boris ^d,e   Solano, Fabio ^f   Rodriguez, Jorge Paz ^g   Alexandrescu, Doru T ^h   De Necochea Campion, Rosalia ^d   Hu, Xiang ⁱ   Marleau, Annette M ^j   Riordan, Neil H ^a  

^a Medistem Inc   (United States)

^b Vet Stem Inc   (United States)

^c UNIVERSITY OF WESTERN ONTARIO   (Canada)

^d UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^e UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^f Cell Medicine Institutes   (Costa Rica)

^g The Stem Cell Institute   (Panama)

^h Georgetown Dermatology   (United States)

ⁱ Shenzhen Beike Cell Engineering Institute   (China)

^j UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

more..

Author keywords

Adipose stem cells; Immune modulation; Stem cell therapy; T regulatory cells; Tolerance induction

Indexed keywords

ADALIMUMAB; AURANOFIN; CASPASE RECRUITMENT DOMAIN PROTEIN 15; CASPASE RECRUITMENT DOMAIN PROTEIN 4; COLLAGEN TYPE 2; CRYOPYRIN; CYTOKINE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; HYDROXYCHLOROQUINE; INFLIXIMAB; INTERFERON REGULATORY FACTOR; LEFLUNOMIDE; LIPOXYGENASE; MELANOMA DIFFERENTIATION ANTIGEN 5; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; NUCLEOTIDE BINDING OLIGOMERIZATION DOMAIN LIKE RECEPTOR; PARACETAMOL; PLACEBO; PROSTAGLANDIN SYNTHASE; PROTEIN TYROSINE KINASE; PYRIMIDINE; RETINOIC ACID INDUCIBLE PROTEIN I; SALAZOSULFAPYRIDINE; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 9; TRIAMCINOLONE ACETONIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ADIPOCYTE; ANTERIOR EYE CHAMBER; ANTIGEN PRESENTING CELL; ARTHRALGIA; CELL ISOLATION; CELL REGENERATION; CELL TRANSPLANTATION; CLINICAL TRIAL; DENDRITIC CELL; ENZYME INHIBITION; HEMATOPOIETIC STEM CELL; HUMAN; IMMUNOLOGICAL TOLERANCE; INHIBITION KINETICS; LIPOSUCTION; LYMPHOCYTE PROLIFERATION; MACROPHAGE; MALIGNANT NEOPLASTIC DISEASE; MESENCHYMAL STEM CELL; MESENCHYMAL STEM CELL TRANSPLANTATION; MOLECULAR MECHANICS; NONHUMAN; PLASTIC SURGERY; PREGNANCY; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION; RECEPTOR UPREGULATION; REGULATORY T LYMPHOCYTE; REVIEW; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; SELF MEDICATION; STROMA CELL; T LYMPHOCYTE ACTIVATION; TISSUE INJURY; TREATMENT OUTCOME;

ADIPOSE TISSUE; AGED; ANIMALS; ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; CELLS, CULTURED; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; JOINTS; LIPECTOMY; MESENCHYMAL STEM CELLS; MOTOR ACTIVITY; PEPTIDES, CYCLIC; RHEUMATOID FACTOR; STEM CELL NICHE; STROMAL CELLS; T-LYMPHOCYTES, REGULATORY;

EID: 77954145557     PISSN: 00088749     EISSN: 10902163     Source Type: Journal    
DOI: 10.1016/j.cellimm.2010.04.002     Document Type: Review

References (229)

1. Riordan N.H., et al. Non-expanded adipose stromal vascular fraction cell therapy for multiple sclerosis. J. Transl. Med. 2009, 7:29.
2. http://www.vet-stem.com/equine/.
3. Black L.L., et al. Effect of adipose-derived mesenchymal stem and regenerative cells on lameness in dogs with chronic osteoarthritis of the coxofemoral joints: a randomized, double-blinded, multicenter, controlled trial. Vet. Ther. 2007, 8(4):272-284.
4. http://www.clinicaltrials.gov/ct2/show/NCT00442806.
5. http://www.clinicaltrials.gov/ct2/show/NCT00426868.
6. http://www.clinicaltrials.gov/ct2/show/NCT00703599.
7. http://www.clinicaltrials.gov/ct2/show/NCT00913289.
8. Zuk P.A., et al. Human adipose tissue is a source of multipotent stem cells. Mol. Biol. Cell 2002, 13(12):4279-4295.
9. Feuerer M., et al. Lean, but not obese, fat is enriched for a unique population of regulatory T cells that affect metabolic parameters. Nat. Med. 2009, 15(8):930-939.
10. Billingham R.E., Brent L., Medawar P.B. Actively acquired tolerance of foreign cells. Nature 1953, 172(4379):603-606.
11. Dutta P., Burlingham W.J. Tolerance to noninherited maternal antigens in mice and humans. Curr. Opin. Organ Transplant. 2009, 14(4):439-447.
12. Clark D.A. Is there any evidence for immunologically mediated or immunologically modifiable early pregnancy failure?. J. Assist. Reprod. Genet. 2003, 20(2):63-72.
13. Gharesi-Fard B., Zolghadri J., Kamali-Sarvestani E. Effect of leukocyte therapy on tumor necrosis factor-α and interferon-γ production in patients with recurrent spontaneous abortion. Am. J. Reprod. Immunol. 2008, 59(3):242-250.
14. Yang H., et al. Proportional change of CD4+CD25+ regulatory T cells after lymphocyte therapy in unexplained recurrent spontaneous abortion patients. Fertil. Steril. 2009, 92(1):301-305.
15. Toder V., et al. Mouse model for the treatment of immune pregnancy loss. Am. J. Reprod. Immunol. 1991, 26(1):42-46.
16. Nonaka T., et al. Results of immunotherapy for patients with unexplained primary recurrent abortions - prospective non-randomized cohort study. Am. J. Reprod. Immunol. 2007, 58(6):530-536.
17. Smith J.B., Fort J.G. Treatment of rheumatoid arthritis by immunization with mononuclear white blood cells: results of a preliminary trial. J. Rheumatol. 1996, 23(2):220-225.
18. Ney J.T., et al. Autochthonous liver tumors induce systemic T cell tolerance associated with T cell receptor down-modulation. Hepatology 2009, 49(2):471-481.
19. Cheung A.F., et al. Regulated expression of a tumor-associated antigen reveals multiple levels of T-cell tolerance in a mouse model of lung cancer. Cancer Res. 2008, 68(22):9459-9468.
20. Bai A., et al. Rapid tolerization of virus-activated tumor-specific CD8+ T cells in prostate tumors of TRAMP mice. Proc. Natl. Acad. Sci. USA 2008, 105(35):13003-13008.
21. Whiteside T.L. Down-regulation of zeta-chain expression in T cells: a biomarker of prognosis in cancer?. Cancer Immunol. Immunother. 2004, 53(10):865-878.
22. Whiteside T.L. Signaling defects in T lymphocytes of patients with malignancy. Cancer Immunol. Immunother. 1999, 48(7):346-352.
23. Reichert T.E., et al. Signaling abnormalities, apoptosis, and reduced proliferation of circulating and tumor-infiltrating lymphocytes in patients with oral carcinoma. Clin. Cancer Res. 2002, 8(10):3137-3145.
24. Park K.S., et al. Type II collagen oral tolerance; mechanism and role in collagen-induced arthritis and rheumatoid arthritis. Mod. Rheumatol. 2009, 19(6):581-589.
25. Womer K.L., et al. A pilot study on the immunological effects of oral administration of donor major histocompatibility complex class II peptides in renal transplant recipients. Clin. Transplant. 2008, 22(6):754-759.
26. Faria A.M., Weiner H.L. Oral tolerance: therapeutic implications for autoimmune diseases. Clin. Dev. Immunol. 2006, 13(2-4):143-157.
27. Thompson H.S., et al. Suppression of collagen induced arthritis by oral administration of type II collagen: changes in immune and arthritic responses mediated by active peripheral suppression. Autoimmunity 1993, 16(3):189-199.
28. Song F., et al. The thymus plays a role in oral tolerance induction in experimental autoimmune encephalomyelitis. Ann. NY Acad. Sci. 2004, 1029:402-404.
29. Hanninen A., Harrison L.C. Mucosal tolerance to prevent type 1 diabetes: can the outcome be improved in humans?. Rev. Diabetes Stud. 2004, 1(3):113-121.
30. Streilein J.W., Niederkorn J.Y. Characterization of the suppressor cell(s) responsible for anterior chamber-associated immune deviation (ACAID) induced in BALB/c mice by P815 cells. J. Immunol. 1985, 134(3):1381-1387.
31. Katagiri K., et al. Using tolerance induced via the anterior chamber of the eye to inhibit Th2-dependent pulmonary pathology. J. Immunol. 2002, 169(1):84-89.
32. Segerer S.E., et al. The glycoprotein-hormones activin A, inhibin A interfere with dendritic cell maturation. Reprod. Biol. Endocrinol. 2008, 6:17.
33. Segerer S.E., et al. Impact of female sex hormones on the maturation and function of human dendritic cells. Am. J. Reprod. Immunol. 2009, 62(3):165-173.
34. Shojaeian J., et al. Immunosuppressive effect of pregnant mouse serum on allostimulatory activity of dendritic cells. J. Reprod. Immunol. 2007, 75(1):23-31.
35. Zarnani A.H., et al. Microenvironment of the feto-maternal interface protects the semiallogenic fetus through its immunomodulatory activity on dendritic cells. Fertil. Steril. 2008, 90(3):781-788.
36. Jurgens B., et al. Interferon-γ-triggered indoleamine-2,3-dioxygenase competence in human monocyte-derived dendritic cells induces regulatory activity in allogeneic T cells. Blood 2009, 114(15):3235-3243.
37. Brenk M., et al. Tryptophan deprivation induces inhibitory receptors ILT3 and ILT4 on dendritic cells favoring the induction of human CD4+CD25+ Foxp3+ T regulatory cells. J. Immunol. 2009, 183(1):145-154.
38. Mellor A.L., et al. Prevention of T cell-driven complement activation and inflammation by tryptophan catabolism during pregnancy. Nat. Immunol. 2001, 2(1):64-68.
39. Lee J.R., et al. Pattern of recruitment of immunoregulatory antigen-presenting cells in malignant melanoma. Lab. Invest. 2003, 83(10):1457-1466.
40. Botella-Estrada R., et al. Cytokine expression and dendritic cell density in melanoma sentinel nodes. Melanoma Res. 2005, 15(2):99-106.
41. Curiel T.J., et al. Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat. Med. 2003, 9(5):562-567.
42. Almand B., et al. Clinical significance of defective dendritic cell differentiation in cancer. Clin. Cancer Res. 2000, 6(5):1755-1766.
43. Almand B., et al. Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J. Immunol. 2001, 166(1):678-689.
44. Zheng X., et al. Reinstalling antitumor immunity by inhibiting tumor-derived immunosuppressive molecule IDO through RNA interference. J. Immunol. 2006, 177(8):5639-5646.
45. Johnson B., et al. Physiology and therapeutics of vascular endothelial growth factor in tumor immunosuppression. Curr. Mol. Med. 2009, 9(6):702-707.
46. Osada T., et al. The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients. Cancer Immunol. Immunother. 2008, 57(8):1115-1124.
47. Min S.Y., et al. Antigen-induced, tolerogenic CD11c+, CD11b+ dendritic cells are abundant in Peyer's patches during the induction of oral tolerance to type II collagen and suppress experimental collagen-induced arthritis. Arthritis Rheum. 2006, 54(3):887-898.
48. Park M.J., et al. Indoleamine 2,3-dioxygenase-expressing dendritic cells are involved in the generation of CD4+CD25+ regulatory T cells in Peyer's patches in an orally tolerized, collagen-induced arthritis mouse model. Arthritis Res. Ther. 2008, 10(1):R11.
49. Viney J.L., et al. Expanding dendritic cells in vivo enhances the induction of oral tolerance. J. Immunol. 1998, 160(12):5815-5825.
50. Shiokawa A., et al. IL-10 and IL-27 producing dendritic cells capable of enhancing IL-10 production of T cells are induced in oral tolerance. Immunol. Lett. 2009, 125(1):7-14.
51. Stein-Streilein J., Watte C. Cross talk among cells promoting anterior chamber-associated immune deviation. Chem. Immunol. Allergy 2007, 92:115-130.
52. Zhang H., et al. Involvement of Foxp3-expressing CD4+ CD25+ regulatory T cells in the development of tolerance induced by transforming growth factor-β2-treated antigen-presenting cells. Immunology 2008, 124(3):304-314.
53. Min W.P., et al. Synergistic tolerance induced by LF15-0195 and anti-CD45RB monoclonal antibody through suppressive dendritic cells. Transplantation 2003, 75(8):1160-1165.
54. Min W.P., et al. Inhibitory feedback loop between tolerogenic dendritic cells and regulatory T cells in transplant tolerance. J. Immunol. 2003, 170:1304-1312.
55. Yang J., et al. LF15-0195 generates tolerogenic dendritic cells by suppression of NF-κB signaling through inhibition of IKK activity. J. Leukoc. Biol. 2003, 74(3):438-447.
56. Min W.P., et al. Dendritic cells genetically engineered to express Fas ligand induce donor-specific hyporesponsiveness and prolong allograft survival. J. Immunol. 2000, 164(1):161-167.
57. Gainer A.L., et al. Improved survival of biolistically transfected mouse islet allografts expressing CTLA4-Ig or soluble Fas ligand. Transplantation 1998, 66(2):194-199.
58. Ichim T.E., et al. RNA interference: a potent tool for gene-specific therapeutics. Am. J. Transplant. 2004, 4(8):1227-1236.
59. Ichim T.E., Zhong R., Min W.P. Prevention of allograft rejection by in vitro generated tolerogenic dendritic cells. Transpl. Immunol. 2003, 11(3-4):295-306.
60. Hill J.A., et al. Immune modulation by silencing IL-12 production in dendritic cells using small interfering RNA. J. Immunol. 2003, 171(2):691-696.
61. Li M., et al. Induction of RNA interference in dendritic cells. Immunol. Res. 2004, 30(2):215-230.
62. Germain R.N. Special regulatory T-cell review: a rose by any other name: from suppressor T cells to Tregs, approbation to unbridled enthusiasm. Immunology 2008, 123(1):20-27.
63. Hall B.M., et al. Specific unresponsiveness in rats with prolonged cardiac allograft survival after treatment with cyclosporine. III. Further characterization of the CD4+ suppressor cell and its mechanisms of action. J. Exp. Med. 1990, 171(1):141-157.
64. Pearce N.W., et al. Specific unresponsiveness in rats with prolonged cardiac allograft survival after treatment with cyclosporine. V. Dependence of CD4+ suppressor cells on the presence of alloantigen and cytokines, including interleukin 2. Transplantation 1993, 55(2):374-380.
65. Sakaguchi S., et al. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor α-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J. Immunol. 1995, 155(3):1151-1164.
66. Ptak W., Gershon R.K. Immunological agnosis: a state that derives from T suppressor cell inhibition of antigen-presenting cells. Proc. Natl. Acad. Sci. USA 1982, 79(8):2645-2648.
67. Min W.P., et al. Inhibitory feedback loop between tolerogenic dendritic cells and regulatory T cells in transplant tolerance. J. Immunol. 2003, 170(3):1304-1312.
68. von Boehmer H. Mechanisms of suppression by suppressor T cells. Nat. Immunol. 2005, 6(4):338-344.
69. Schumacher A., et al. Human chorionic gonadotropin attracts regulatory T cells into the fetal-maternal interface during early human pregnancy. J. Immunol. 2009, 182(9):5488-5497.
70. Jin L.P., et al. The CD4(+)CD25(bright) regulatory T cells, CTLA-4 expression in peripheral, decidual lymphocytes are down-regulated in human miscarriage. Clin. Immunol. 2009, 133(3):402-410.
71. Arruvito L., et al. IL-6 trans-signaling, the frequency of CD4+FOXP3+ cells in women with reproductive failure. J. Reprod. Immunol. 2009, 82(2):158-165.
72. Li W., et al. CTLA4Ig gene transfer alleviates abortion in mice by expanding CD4+CD25+ regulatory T cells and inducing indoleamine-2,3-dioxygenase. J. Reprod. Immunol. 2009, 80(1-2):1-11.
73. Perrone G., et al. Intratumoural FOXP3-positive regulatory T cells are associated with adverse prognosis in radically resected gastric cancer. Eur. J. Cancer 2008, 44(13):1875-1882.
74. Petersen R.P., et al. Tumor infiltrating Foxp3+ regulatory T-cells are associated with recurrence in pathologic stage I NSCLC patients. Cancer 2006, 107(12):2866-2872.
75. Sinicrope F.A., et al. Intraepithelial effector (CD3+)/regulatory (FoxP3+) T-cell ratio predicts a clinical outcome of human colon carcinoma. Gastroenterology 2009, 137(4):1270-1279.
76. Merlo A., et al. FOXP3 expression and overall survival in breast cancer. J. Clin. Oncol. 2009, 27(11):1746-1752.
77. Goforth R., et al. Immune stimulatory antigen loaded particles combined with depletion of regulatory T-cells induce potent tumor specific immunity in a mouse model of melanoma. Cancer Immunol. Immunother. 2009, 58(4):517-530.
78. Rech A.J., Vonderheide R.H. Clinical use of anti-CD25 antibody daclizumab to enhance immune responses to tumor antigen vaccination by targeting regulatory T cells. Ann. NY Acad. Sci. 2009, 1174:99-106.
79. Faria A.M., Weiner H.L. Oral tolerance and TGF-β-producing cells. Inflamm. Allergy Drug Targets 2006, 5(3):179-190.
80. Carrier Y., et al. Th3 cells in peripheral tolerance. I. Induction of Foxp3-positive regulatory T cells by Th3 cells derived from TGF-β T cell-transgenic mice. J. Immunol. 2007, 178(1):179-185.
81. Sonoda K.H., et al. NKT cell-derived urokinase-type plasminogen activator promotes peripheral tolerance associated with eye. J. Immunol. 2007, 179(4):2215-2222.
82. Nakamura K., Kitani A., Strober W. Cell contact-dependent immunosuppression by CD4(+)CD25(+) regulatory T cells is mediated by cell surface-bound transforming growth factor β. J. Exp. Med. 2001, 194(5):629-644.
83. Ghiringhelli F., et al. CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-β-dependent manner. J. Exp. Med. 2005, 202(8):1075-1085.
84. Kelchtermans H., et al. Activated CD4+CD25+ regulatory T cells inhibit osteoclastogenesis and collagen-induced arthritis. Ann. Rheum. Dis. 2009, 68(5):744-750.
85. Cao X., et al. Granzyme B and perforin are important for regulatory T cell-mediated suppression of tumor clearance. Immunity 2007, 27(4):635-646.
86. Vezys V., Lefrancois L. Cutting edge: inflammatory signals drive organ-specific autoimmunity to normally cross-tolerizing endogenous antigen. J. Immunol. 2002, 169(12):6677-6680.
87. Oehen S., et al. Vaccination or tolerance to prevent diabetes. Eur. J. Immunol. 1992, 22(12):3149-3153.
88. Matzinger P. The danger model: a renewed sense of self. Science 2002, 296(5566):301-305.
89. Baccala R., et al. Sensors of the innate immune system: their mode of action. Nat. Rev. Rheumatol. 2009, 5(8):448-456.
90. Rehwinkel J., et al. RIG-I detects viral genomic RNA during negative-strand RNA virus infection. Cell 2010, 140(3):397-408.
91. Choi M.K., et al. A selective contribution of the RIG-I-like receptor pathway to type I interferon responses activated by cytosolic DNA. Proc. Natl. Acad. Sci. USA 2009, 106(42):17870-17875.
92. Takaoka A., et al. DAI (DLM-1/ZBP1) is a cytosolic DNA sensor and an activator of innate immune response. Nature 2007, 448(7152):501-505.
93. Riley J.K., Nelson D.M. Toll-like receptors in pregnancy disorders and placental dysfunction. Clin. Rev. Allergy Immunol. 2009, October 29 [Epub ahead of print].
94. Friedberg J.W., et al. Phase II study of a TLR-9 agonist (1018 ISS) with rituximab in patients with relapsed or refractory follicular lymphoma. Br. J. Haematol. 2009, 146(3):282-291.
95. Murad Y.M., et al. CPG-7909 (PF-3512676, ProMune): toll-like receptor-9 agonist in cancer therapy. Expert Opin. Biol. Ther. 2007, 7(8):1257-1266.
96. Chung Y., et al. NKT cell ligand α-galactosylceramide blocks the induction of oral tolerance by triggering dendritic cell maturation. Eur. J. Immunol. 2004, 34(9):2471-2479.
97. Brix S., et al. Lipopolysaccharide contamination of β-lactoglobulin affects the immune response against intraperitoneally and orally administered antigen. Int. Arch. Allergy Immunol. 2004, 135(3):216-220.
98. Watanabe T., et al. High mobility group box protein-1 in experimental autoimmune uveoretinitis. Invest. Ophthalmol. Vis. Sci. 2009, 50(5):2283-2290.
99. Lei F., et al. A penetrating ocular injury can affect the induction of anterior chamber-associated immune deviation. Mol. Vis. 2008, 14:327-333.
100. Emery P., Luqmani R. The validity of surrogate markers in rheumatic disease. Br. J. Rheumatol. 1993, 32(Suppl. 3):3-8.
101. Cemerski S., van Meerwijk J.P., Romagnoli P. Oxidative-stress-induced T lymphocyte hyporesponsiveness is caused by structural modification rather than proteasomal degradation of crucial TCR signaling molecules. Eur. J. Immunol. 2003, 33(8):2178-2185.
102. Lee E.K., et al. Essential roles of toll-like receptor-4 signaling in arthritis induced by type II collagen antibody and LPS. Int. Immunol. 2005, 17(3):325-333.
103. Roelofs M.F., et al. Identification of small heat shock protein B8 (HSP22) as a novel TLR4 ligand and potential involvement in the pathogenesis of rheumatoid arthritis. J. Immunol. 2006, 176(11):7021-7027.
104. Huang Q.Q., et al. Heat shock protein 96 is elevated in rheumatoid arthritis and activates macrophages primarily via TLR2 signaling. J. Immunol. 2009, 182(8):4965-4973.
105. Brentano F., et al. RNA released from necrotic synovial fluid cells activates rheumatoid arthritis synovial fibroblasts via toll-like receptor 3. Arthritis Rheum. 2005, 52(9):2656-2665.
106. Pasare C., Medzhitov R. Toll pathway-dependent blockade of CD4+CD25+ T cell-mediated suppression by dendritic cells. Science 2003, 299(5609):1033-1036.
107. Valencia X., et al. TNF downmodulates the function of human CD4+CD25hi T-regulatory cells. Blood 2006, 108(1):253-261.
108. Coulombe M., et al. Tolerance to antigen-presenting cell-depleted islet allografts is CD4 T cell dependent. J. Immunol. 1999, 162(5):2503-2510.
109. Han J., et al. Adipose tissue is an extramedullary reservoir for functional hematopoietic stem, progenitor cells. Blood 2010, 115(5):957-964.
110. Zannettino A.C., et al. Multipotential human adipose-derived stromal stem cells exhibit a perivascular phenotype in vitro and in vivo. J. Cell. Physiol. 2008, 214(2):413-421.
111. Hoogduijn M.J., et al. Human heart, spleen, and perirenal fat-derived mesenchymal stem cells have immunomodulatory capacities. Stem Cells Dev. 2007, 16(4):597-604.
112. Chao K.C., et al. Islet-like clusters derived from mesenchymal stem cells in Wharton's Jelly of the human umbilical cord for transplantation to control type 1 diabetes. PLoS One 2008, 3(1):e1451.
113. Jo Y.Y., et al. Isolation and characterization of postnatal stem cells from human dental tissues. Tissue Eng. 2007, 13(4):767-773.
114. He Q., Wan C., Li G. Concise review: multipotent mesenchymal stromal cells in blood. Stem Cells 2007, 25(1):69-77.
115. Oh W., et al. Immunological properties of umbilical cord blood-derived mesenchymal stromal cells. Cell. Immunol. 2008, 251(2):116-123.
116. Meng X., et al. Endometrial regenerative cells: a novel stem cell population. J. Transl. Med. 2007, 5:57.
117. Hida N., et al. Novel cardiac precursor-like cells from human menstrual blood-derived mesenchymal cells. Stem Cells 2008, 26(7):1695-1704.
118. Patel A.N., et al. Multipotent menstrual blood stromal stem cells: isolation, characterization, and differentiation. Cell Transplant. 2008, 17(3):303-311.
119. Le Blanc K., Ringden O. Immunomodulation by mesenchymal stem cells and clinical experience. J. Intern. Med. 2007, 262(5):509-525.
120. Keyser K.A., Beagles K.E., Kiem H.P. Comparison of mesenchymal stem cells from different tissues to suppress T-cell activation. Cell Transplant. 2007, 16(5):555-562.
121. Nasef A., et al. Identification of IL-10 and TGF-β transcripts involved in the inhibition of T-lymphocyte proliferation during cell contact with human mesenchymal stem cells. Gene Expr. 2007, 13(4-5):217-226.
122. Ryan J.M., et al. Interferon-γ does not break, but promotes the immunosuppressive capacity of adult human mesenchymal stem cells. Clin. Exp. Immunol. 2007, 149(2):353-363.
123. Nasef A., et al. Leukemia inhibitory factor: role in human mesenchymal stem cells mediated immunosuppression. Cell. Immunol. 2008, 253(1-2):16-22.
124. Selmani Z., et al. Human leukocyte antigen-G5 secretion by human mesenchymal stem cells is required to suppress T lymphocyte and natural killer function and to induce CD4+CD25 high FOXP3+ regulatory T cells. Stem Cells 2008, 26(1):212-222.
125. Ortiz L.A., et al. Interleukin 1 receptor antagonist mediates the antiinflammatory and antifibrotic effect of mesenchymal stem cells during lung injury. Proc. Natl. Acad. Sci. USA 2007, 104(26):11002-11007.
126. English K., et al. IFN-γ and TNF-α differentially regulate immunomodulation by murine mesenchymal stem cells. Immunol. Lett. 2007, 110(2):91-100.
127. Jones B.J., et al. Immunosuppression by placental indoleamine-2,3-dioxygenase: a role for mesenchymal stem cells. Placenta 2007, 28(11-12):1174-1181.
128. Ko E., et al. Mesenchymal stem cells inhibit the differentiation of CD4+ T cells into interleukin-17-secreting T cells. Acta Haematol. 2008, 120(3):165-167.
129. Casiraghi F., et al. Pretransplant infusion of mesenchymal stem cells prolongs the survival of a semiallogeneic heart transplant through the generation of regulatory T cells. J. Immunol. 2008, 181(6):3933-3946.
130. Kassis I., et al. Neuroprotection and immunomodulation with mesenchymal stem cells in chronic experimental autoimmune encephalomyelitis. Arch. Neurol. 2008, 65(6):753-761.
131. Parekkadan B., Tilles A.W., Yarmush M.L. Bone marrow-derived mesenchymal stem cells ameliorate autoimmune enteropathy independently of regulatory T cells. Stem Cells 2008, 26(7):1913-1919.
132. Li H., et al. Mesenchymal stem cells alter migratory property of T and dendritic cells to delay the development of murine lethal acute graft-versus-host disease. Stem Cells 2008, 26(10):2531-2541.
133. Augello A., et al. Cell therapy using allogeneic bone marrow mesenchymal stem cells prevents tissue damage in collagen-induced arthritis. Arthritis Rheum. 2007, 56(4):1175-1186.
134. Semedo P., et al. Mesenchymal stem cells ameliorate tissue damages triggered by renal ischemia and reperfusion injury. Transplant. Proc. 2007, 39(2):421-423.
135. Le Blanc K., et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 2008, 371(9624):1579-1586.
136. Ning H., et al. The correlation between cotransplantation of mesenchymal stem cells and higher recurrence rate in hematologic malignancy patients: outcome of a pilot clinical study. Leukemia 2008, 22(3):593-599.
137. Ball L., et al. Third party mesenchymal stromal cell infusions fail to induce tissue repair despite successful control of severe grade IV acute graft-versus-host disease in a child with juvenile myelo-monocytic leukemia. Leukemia 2008, 22(6):1256-1257.
138. Ringden O., et al. Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. Transplantation 2006, 81(10):1390-1397.
139. Le Blanc K., et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 2004, 363(9419):1439-1441.
140. Muller I., et al. Application of multipotent mesenchymal stromal cells in pediatric patients following allogeneic stem cell transplantation. Blood Cells Mol. Dis. 2008, 40(1):25-32.
141. Sun L., et al. Mesenchymal stem cell transplantation reverses multiorgan dysfunction in systemic lupus erythematosus mice and humans. Stem Cells 2009, 27(6):1421-1432.
142. Kharaziha P., et al. Improvement of liver function in liver cirrhosis patients after autologous mesenchymal stem cell injection: a phase I-II clinical trial. Eur. J. Gastroenterol. Hepatol. 2009, 21(10):1199-1205.
143. Taguchi A., et al. Administration of CD34+ cells after stroke enhances neurogenesis via angiogenesis in a mouse model. J. Clin. Invest. 2004, 114(3):330-338.
144. Yoshioka T., et al. Repair of infarcted myocardium mediated by transplanted bone marrow-derived CD34+ stem cells in a nonhuman primate model. Stem Cells 2005, 23(3):355-364.
145. Wang X., et al. Albumin-expressing hepatocyte-like cells develop in the livers of immune-deficient mice that received transplants of highly purified human hematopoietic stem cells. Blood 2003, 101(10):4201-4208.
146. http://www.clinicaltrials.gov/ct2/show/NCT00313339.
147. http://www.clinicaltrials.gov/ct2/show/NCT00950521.
148. http://www.clinicaltrials.gov/ct2/show/NCT00062543.
149. Massengale M., et al. Hematopoietic cells maintain hematopoietic fates upon entering the brain. J. Exp. Med. 2005, 201(10):1579-1589.
150. Balsam L.B., et al. Haematopoietic stem cells adopt mature haematopoietic fates in ischaemic myocardium. Nature 2004, 428(6983):668-673.
151. Majka M., et al. Numerous growth factors, cytokines, and chemokines are secreted by human CD34(+) cells, myeloblasts, erythroblasts, and megakaryoblasts and regulate normal hematopoiesis in an autocrine/paracrine manner. Blood 2001, 97(10):3075-3085.
152. Kudo F.A., et al. Autologous transplantation of peripheral blood endothelial progenitor cells (CD34+) for therapeutic angiogenesis in patients with critical limb ischemia. Int. Angiol. 2003, 22(4):344-348.
153. Reisner Y., Martelli M.F. Tolerance induction by 'megadose' transplants of CD34+ stem cells: a new option for leukemia patients without an HLA-matched donor. Curr. Opin. Immunol. 2000, 12(5):536-541.
154. Rachamim N., et al. Tolerance induction by " megadose" hematopoietic transplants: donor-type human CD34 stem cells induce potent specific reduction of host anti-donor cytotoxic T lymphocyte precursors in mixed lymphocyte culture. Transplantation 1998, 65(10):1386-1393.
155. George J.F., et al. An essential role for Fas ligand in transplantation tolerance induced by donor bone marrow. Nat. Med. 1998, 4(3):333-335.
156. Brazil J.J., Gupta P. Constitutive expression of the Fas receptor and its ligand in adult human bone marrow: a regulatory feedback loop for the homeostatic control of hematopoiesis. Blood Cells Mol. Dis. 2002, 29(1):94-103.
157. Gur H., et al. Immune regulatory activity of CD34+ progenitor cells: evidence for a deletion-based mechanism mediated by TNF-α. Blood 2005, 105(6):2585-2593.
158. Wahl S.M., Wen J., Moutsopoulos N. TGF-β: a mobile purveyor of immune privilege. Immunol. Rev. 2006, 213:213-227.
159. Lewkowicz P., et al. Lipopolysaccharide-activated CD4+CD25+ T regulatory cells inhibit neutrophil function and promote their apoptosis and death. J. Immunol. 2006, 177(10):7155-7163.
160. Mahajan D., et al. CD4+CD25+ regulatory T cells protect against injury in an innate murine model of chronic kidney disease. J. Am. Soc. Nephrol. 2006, 17(10):2731-2741.
161. Hatzfeld J., et al. Purification and release from quiescence of umbilical cord blood early progenitors reveal their potential to engraft adults. Blood Cells 1994, 20(2-3):430-434. (discussion 434-435).
162. Hatzfeld J., et al. Release of early human hematopoietic progenitors from quiescence by antisense transforming growth factor β1 or Rb oligonucleotides. J. Exp. Med. 1991, 174(4):925-929.
163. Akel S., et al. Neutralization of autocrine transforming growth factor-β in human cord blood CD34(+)CD38(-)Lin(-) cells promotes stem-cell-factor-mediated erythropoietin-independent early erythroid progenitor development and reduces terminal differentiation. Stem Cells 2003, 21(5):557-567.
164. Batard P., et al. TGF-β1 maintains hematopoietic immaturity by a reversible negative control of cell cycle and induces CD34 antigen up-modulation. J. Cell Sci. 2000, 113(Pt. 3):383-390.
165. Kared H., et al. Jagged2-expressing hematopoietic progenitors promote regulatory T cell expansion in the periphery through notch signaling. Immunity 2006, 25(5):823-834.
166. Massberg S., et al. Immunosurveillance by hematopoietic progenitor cells trafficking through blood, lymph, and peripheral tissues. Cell 2007, 131(5):994-1008.
167. De Rosa V., et al. A key role of leptin in the control of regulatory T cell proliferation. Immunity 2007, 26(2):241-255.
168. Chatenoud L. CD3-specific antibody-induced active tolerance: from bench to bedside. Nat. Rev. Immunol. 2003, 3(2):123-132.
169. Kelley's Textbook of Rheumatology 2005, vol. 7:996-1042. Elsevier Saunders, Philadelphia, USA.
170. Sun S., et al. TLR7/9 antagonists as therapeutics for immune-mediated inflammatory disorders. Inflamm. Allergy Drug Targets 2007, 6(4):223-235.
171. Chong A.S., et al. In vivo activity of leflunomide: pharmacokinetic analyses and mechanism of immunosuppression. Transplantation 1999, 68(1):100-109.
172. Dimitrova P., et al. Restriction of de novo pyrimidine biosynthesis inhibits Th1 cell activation and promotes Th2 cell differentiation. J. Immunol. 2002, 169(6):3392-3399.
173. Kirsch B.M., et al. The active metabolite of leflunomide, A77 1726, interferes with dendritic cell function. Arthritis Res. Ther. 2005, 7(3):R694-R703.
174. Tepperman K., et al. Dicyanogold effects on lymphokine production. Met. Based Drugs 1999, 6(4-5):301-309.
175. Han S., et al. Auranofin, an immunosuppressive drug, inhibits MHC class I and MHC class II pathways of antigen presentation in dendritic cells. Arch. Pharm. Res. 2008, 31(3):370-376.
176. Kim T.S., et al. Inhibition of interleukin-12 production by auranofin, an anti-rheumatic gold compound, deviates CD4(+) T cells from the Th1 to the Th2 pathway. Br. J. Pharmacol. 2001, 134(3):571-578.
177. Taggart A.J. Sulphasalazine in arthritis - an old drug rediscovered. Clin. Rheumatol. 1987, 6(3):378-383.
178. Bansard C., et al. Can rheumatoid arthritis responsiveness to methotrexate and biologics be predicted?. Rheumatology (Oxford) 2009, 48(9):1021-1028.
179. Bijlsma J.W., et al. Are glucocorticoids DMARDs?. Ann. NY Acad. Sci. 2006, 1069:268-274.
180. Nanda S., Bathon J.M. Etanercept: a clinical review of current and emerging indications. Expert Opin. Pharmacother. 2004, 5(5):1175-1186.
181. Shakoor N., et al. Drug-induced systemic lupus erythematosus associated with etanercept therapy. Lancet 2002, 359(9306):579-580.
182. Dinarello C.A. Anti-cytokine therapeutics and infections. Vaccine 2003, 21(Suppl. 2):S24-S34.
183. Trentham D.E., Townes A.S., Kang A.H. Autoimmunity to type II collagen an experimental model of arthritis. J. Exp. Med. 1977, 146(3):857-868.
184. Trentham D.E., Dynesius R.A., David J.R. Passive transfer by cells of type II collagen-induced arthritis in rats. J. Clin. Invest. 1978, 62(2):359-366.
185. Londei M., et al. Persistence of collagen type II-specific T-cell clones in the synovial membrane of a patient with rheumatoid arthritis. Proc. Natl. Acad. Sci. USA 1989, 86(2):636-640.
186. Sekine T., et al. Type II collagen is a target antigen of clonally expanded T cells in the synovium of patients with rheumatoid arthritis. Ann. Rheum. Dis. 1999, 58(7):446-450.
187. Trentham D.E., et al. Effects of oral administration of type II collagen on rheumatoid arthritis. Science 1993, 261(5129):1727-1730.
188. http://www.autoimmuneinc.com/clinic/coll.html.
189. Nasef A., et al. Selected Stro-1-enriched bone marrow stromal cells display a major suppressive effect on lymphocyte proliferation. Int. J. Lab. Hematol. 2009, 31(1):9-19.
190. Lepelletier Y., et al. Galectin-1, semaphorin-3A are two soluble factors conferring T cell immunosuppression to bone marrow mesenchymal stem cell. Stem Cells Dev. 2009, November 3 [Epub ahead of print].
191. Renner P., et al. Mesenchymal stem cells require a sufficient, ongoing immune response to exert their immunosuppressive function. Transplant. Proc. 2009, 41(6):2607-2611.
192. Lisheng W., Meng E., Guo Z. High mobility group box 1 protein inhibits the proliferation of human mesenchymal stem cells and promotes their migration and differentiation along osteoblastic pathway. Stem Cells Dev. 2008, March 14 [Epub ahead of print].
193. Kitaori T., et al. Stromal cell-derived factor 1/CXCR4 signaling is critical for the recruitment of mesenchymal stem cells to the fracture site during skeletal repair in a mouse model. Arthritis Rheum. 2009, 60(3):813-823.
194. Wang Y., Deng Y., Zhou G.Q. SDF-1α/CXCR4-mediated migration of systemically transplanted bone marrow stromal cells towards ischemic brain lesion in a rat model. Brain Res. 2008, 1195:104-112.
195. Shi M., et al. Regulation of CXCR4 expression in human mesenchymal stem cells by cytokine treatment: role in homing efficiency in NOD/SCID mice. Haematologica 2007, 92(7):897-904.
196. Gunzberg W.H., Salmons B. Stem cell therapies: on track but suffer setback. Curr. Opin. Mol. Ther. 2009, 11(4):360-363.
197. Kebriaei P., et al. Adult human mesenchymal stem cells added to corticosteroid therapy for the treatment of acute graft-versus-host disease. Biol. Blood Marrow Transplant. 2009, 15(7):804-811.
198. Dryden G.W. Overview of stem cell therapy for Crohn's disease. Expert Opin. Biol. Ther. 2009, 9(7):841-847.
199. Richardson S.M., et al. Mesenchymal stem cells in regenerative medicine: opportunities and challenges for articular cartilage and intervertebral disc tissue engineering. J. Cell. Physiol. 2010, 222(1):23-32.
200. Bouffi C., et al. Multipotent mesenchymal stromal cells and rheumatoid arthritis: risk or benefit?. Rheumatology (Oxford) 2009, 48(10):1185-1189.
201. Nakagawa S., et al. Bone marrow stromal cells contribute to synovial cell proliferation in rats with collagen induced arthritis. J. Rheumatol. 1996, 23(12):2098-2103.
202. Ochi T., et al. Mesenchymal stromal cells. Nurse-like cells reside in the synovial tissue and bone marrow in rheumatoid arthritis. Arthritis Res. Ther. 2007, 9(1):201.
203. Kastrinaki M.C., et al. Functional, molecular and proteomic characterisation of bone marrow mesenchymal stem cells in rheumatoid arthritis. Ann. Rheum. Dis. 2008, 67(6):741-749.
204. Papadaki H.A., et al. Bone marrow progenitor cell reserve and function and stromal cell function are defective in rheumatoid arthritis: evidence for a tumor necrosis factor α-mediated effect. Blood 2002, 99(5):1610-1619.
205. Djouad F., et al. Reversal of the immunosuppressive properties of mesenchymal stem cells by tumor necrosis factor α in collagen-induced arthritis. Arthritis Rheum. 2005, 52(5):1595-1603.
206. Mao F., et al. Immunosuppressive effects of mesenchymal stem cells in collagen-induced mouse arthritis. Inflamm. Res. 2010, 59(3):219-225.
207. Gonzalez M.A., et al. Treatment of experimental arthritis by inducing immune tolerance with human adipose-derived mesenchymal stem cells. Arthritis Rheum. 2009, 60(4):1006-1019.
208. Zheng Z.H., et al. Allogeneic mesenchymal stem cell and mesenchymal stem cell-differentiated chondrocyte suppress the responses of type II collagen-reactive T cells in rheumatoid arthritis. Rheumatology (Oxford) 2008, 47(1):22-30.
209. Karussis D., Kassis I. The potential use of stem cells in multiple sclerosis: an overview of the preclinical experience. Clin. Neurol. Neurosurg. 2008, 110(9):889-896.
210. Zappia E., et al. Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy. Blood 2005, 106(5):1755-1761.
211. Boumaza I., et al. Autologous bone marrow-derived rat mesenchymal stem cells promote PDX-1, insulin expression in the islets, alter T cell cytokine pattern, preserve regulatory T cells in the periphery, induce sustained normoglycemia. J. Autoimmun. 2009, 32(1):33-42.
212. Zhou K., et al. Transplantation of human bone marrow mesenchymal stem cell ameliorates the autoimmune pathogenesis in MRL/lpr mice. Cell. Mol. Immunol. 2008, 5(6):417-424.
213. Fuchtenbusch M., et al. Delay of type I diabetes in high risk, first degree relatives by parenteral antigen administration: the Schwabing Insulin Prophylaxis Pilot Trial. Diabetologia 1998, 41(5):536-541.
214. Darlington C. MBP-8298, a synthetic peptide analog of myelin basic protein for the treatment of multiple sclerosis. Curr. Opin. Mol. Ther. 2007, 9(4):398-402.
215. Xi C., et al. A novel recombinant peptide containing only two T-cell tolerance epitopes of chicken type II collagen that suppresses collagen-induced arthritis. Mol. Immunol. 2009, 46(4):729-737.
216. Kamphuis S., et al. Tolerogenic immune responses to novel T-cell epitopes from heat-shock protein 60 in juvenile idiopathic arthritis. Lancet 2005, 366(9479):50-56.
217. Popov I., et al. Preventing autoimmune arthritis using antigen-specific immature dendritic cells: a novel tolerogenic vaccine. Arthritis Res. Ther. 2006, 8(5):R141.
218. Friedman A., et al. Oral tolerance: a biologically relevant pathway to generate peripheral tolerance against external and self antigens. Chem. Immunol. 1994, 58:259-290.
219. Chen G., et al. Glutamic acid decarboxylase-derived epitopes with specific domains expand CD4(+)CD25(+) regulatory T cells. PLoS One 2009, 4(9):e7034.
220. Rakhmilevich A.L., North R.J., Dye E.S. Presence of CD4+ T suppressor cells in mice rendered unresponsive to tumor antigens by intravenous injection of irradiated tumor cells. Int. J. Cancer 1993, 55(2):338-343.
221. Seidel-Guyenot W., et al. Low zone tolerance induced by systemic application of allergens inhibits Tc1-mediated skin inflammation. J. Allergy Clin. Immunol. 2006, 117(5):1170-1177.
222. Fischer R., et al. Use of rapamycin in the induction of tolerogenic dendritic cells. Handb. Exp. Pharmacol. 2009, 188:215-232.
223. Onishi Y., et al. Foxp3+ natural regulatory T cells preferentially form aggregates on dendritic cells in vitro and actively inhibit their maturation. Proc. Natl. Acad. Sci. USA 2008, 105(29):10113-10118.
224. Mahnke K., et al. Induction of immunosuppressive functions of dendritic cells in vivo by CD4+CD25+ regulatory T cells: role of B7-H3 expression and antigen presentation. Eur. J. Immunol. 2007, 37(8):2117-2126.
225. Spaggiari G.M., et al. MSCs inhibit monocyte-derived DC maturation and function by selectively interfering with the generation of immature DCs: central role of MSC-derived prostaglandin E2. Blood 2009, 113(26):6576-6583.
226. Herold K.C., et al. Treatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb Teplizumab preserves insulin production for up to 5 years. Clin. Immunol. 2009, 132(2):166-173.
227. Hang-Fu L., Marmolya G., Feiglin D.H. Liposuction fat-fillant implant for breast augmentation and reconstruction. Aesthetic Plast. Surg. 1995, 19(5):427-437.
228. Klein A.W. Skin filling. Collagen and other injectables of the skin. Dermatol. Clin. 2001, 19(3):491-508. (ix).
229. Esensten J.H., Wofsy D., Bluestone J.A. Regulatory T cells as therapeutic targets in rheumatoid arthritis. Nat. Rev. Rheumatol. 2009, 5(10):560-565.